8-K: Nutex posts restated Q1 2025 profit and cash surge

Nutex Health restated Q1 2025 results show a sharp swing to profitability, 214% revenue growth, record operating cash flow, and higher EPS after non-cash reclassifications.

Summary

• Restated Q1 2025 revenue was $211.789 million, up 214.0% from $67.453 million in Q1 2024.
• Net income attributable to Nutex was $21.217 million (vs. a $0.364 million loss in Q1 2024); diluted EPS was $3.33 and basic EPS $3.74.
• EBITDA was $51.542 million; Adjusted EBITDA was $72.821 million (vs. $(0.412) million in Q1 2024).
• Operating income rose to $80.661 million; gross profit was $118.338 million, reflecting a 55.9% gross margin.
• Hospital division revenue was $203.947 million; population health revenue was $7.842 million.
• Total visits were 48,269 (+20.5% YoY); mature hospital visits increased 5.3%, and mature hospital revenue grew 186.5% YoY.
• Net cash from operating activities was $50.965 million; cash and equivalents were $84.729 million at quarter-end.
• Long-term debt, net was $21.733 million; accounts receivable were $295.082 million.
• Restatement was driven by non-cash reclassifications: $20.7 million stock-based comp obligations to liabilities, $3.5 million related-party AP reclass to equity, $2.9 million restricted cash to short-term investments, and +$2.4 million accrued income tax expense.
• As a result of the restatement: liabilities increased by $19.6 million (4.0%), equity decreased by $19.6 million (7.1%), and net income increased by $6.6 million (14.9%).

Sentiment

Score: 7

Explanation: Financial performance and cash generation were strong, with positive IDR outcomes, but reliance on arbitration, high receivables, significant accrued liabilities, and non-cash stock compensation obligations temper the outlook.

Positives

• Significant top-line growth: revenue up 214.0% YoY to $211.789 million.
• Swing to profitability: $21.217 million net income attributable to Nutex vs. a loss in Q1 2024; diluted EPS $3.33.
• Strong cash generation: $50.965 million net cash from operating activities; cash balance of $84.729 million.
• EBITDA of $51.542 million and Adjusted EBITDA of $72.821 million, indicating improved operating performance.
• Gross margin at 55.9% and operating income of $80.661 million.
• Hospital division momentum: 48,269 visits (+20.5% YoY); mature hospital revenue up 186.5%.
• Company indicates improved payment outcomes from IDR arbitration with insurers.

Negatives

• Large non-cash stock-based compensation expense of $27.642 million in the quarter (primarily one-time obligations for under-construction and ramping hospitals).
• High accounts receivable balance of $295.082 million, implying working capital intensity and potential collection risk.
• Accrued arbitration expenses of $51.803 million and accrued income tax expense of $46.130 million contribute to sizable current liabilities.
• Results rely partly on favorable outcomes from the IDR process, which may not be consistently replicable.

Risks

• Ability to execute the growth strategy as planned.
• Changes in laws or regulations, including interim and final rules under the No Surprises Act.
• Economic conditions that may impact utilization and payer behavior.
• Dependence on management and potential dilution to stockholders.
• Potential lack of capital and the effects of rapid growth on operations.
• Competitive pressures and the Company’s ability to compete effectively.
• Conflicts of interest in related party transactions.
• Regulatory matters and protection of technology; lack of industry standards.
• Ability to obtain future financing on acceptable terms.
• Outcome and consistency of payments obtained via the Independent Dispute Resolution (IDR) arbitration process.

Future Outlook

Management highlights continued momentum from 2024 into Q1 2025, citing volume growth, operational efficiency, and improved payments via the IDR arbitration process as drivers of more consistent results while executing the 2025 growth plan.

Management Comments

• CFO: Excited to report $21.2 million in net income, a record-high gross profit of 55.9%, record $51.0 million in net cash from operating activities, and a record cash balance of $84.7 million, all restated and materially consistent with original results.
• CEO: Momentum from 2024 is continuing into Q1 2025, with more consistent financial results from volume growth, operational efficiency, and more fair and reasonable payments from the arbitration process; appreciation expressed for physicians and team members.

Industry Context

Results reflect tailwinds from the No Surprises Act’s IDR process, which can improve out-of-network reimbursement for emergency care providers. Micro-hospitals and HOPDs have been gaining traction as lower-capital, distributed access points versus large inpatient campuses. Payment environment remains sensitive to payer disputes and evolving NSA rules, a dynamic affecting emergency medicine groups and hospital operators broadly.

Comparison to Industry Standards

• Revenue growth of 214% YoY substantially exceeds large hospital operators, which have generally reported single-digit to low-teens growth; Nutex’s model and IDR recoveries are contributing factors.
• Adjusted EBITDA margin implied near 34% (72.8/211.8) is higher than many scaled hospital peers (e.g., HCA Healthcare, Tenet Healthcare, Surgery Partners typically in mid-teens to ~20% ranges on adjusted basis), though Nutex’s margin may be buoyed by specific arbitration-driven recoveries and model mix.
• Operating cash flow of ~$51 million on $212 million revenue indicates strong cash conversion for the quarter; sustainability vs. industry hinges on collections from payers and IDR outcomes.
• Visit growth of 20.5% outpaces the modest volume growth reported by larger systems, consistent with an expansionary footprint and micro-hospital ramp dynamics.

Corporate Governance

Legal Proceedings

• Ongoing use of Independent Dispute Resolution (IDR) arbitration with insurers under the No Surprises Act; accrued arbitration expenses totaled $51.803 million as of March 31, 2025.

Related Party Transactions

• Reclassified related-party accounts payable balances of $3.5 million from liabilities to equity as part of the restatement.
• Accounts receivable—related parties were $4.258 million as of March 31, 2025.

Stakeholder Impact

• Shareholders: Swing to profitability and stronger cash position are positive; restatement increases EPS but highlights accounting complexity.
• Employees and Physicians: Operational momentum and higher volumes support stability and potential growth opportunities.
• Customers/Patients: Expanded access and throughput via micro-hospitals and HOPDs; potential benefits from improved insurer payment consistency.
• Suppliers/Creditors: Strong operating cash flow and low net long-term debt ($21.733 million) improve credit profile.
• Payers: Continued arbitration activity may increase reimbursement obligations, affecting payer-provider dynamics.

Next Steps

• Continue executing the 2025 growth plan across micro-hospitals and HOPDs.
• Sustain IDR arbitration efforts to secure fair and reasonable payments from insurers.
• Maintain operational efficiency and volume growth initiatives.
• Investors referred to the Amended Form 10-Q/A for detailed restated financials.

Key Dates

Recommendation

The quarter exhibits strong growth, profitability, and cash generation, supported by favorable IDR outcomes, but elevated receivables, substantial accrued arbitration and tax liabilities, and heavy (though largely one-time) stock-based compensation introduce execution and collection risks. Given regulatory and payer uncertainty around the No Surprises Act and reliance on arbitration, a balanced stance is warranted pending evidence of sustained collections and cash conversion.

Keywords

Nutex Health, restatement, Q1 2025, micro-hospitals, No Surprises Act, Independent Dispute Resolution, IDR arbitration, Adjusted EBITDA, stock-based compensation, hospital outpatient department, HOPD, population health, physician-led, cash flow, EPS